AbbVie lowers its FY24 adjusted EPS guidance following acquired IPR&D and milestones expenses (195.45 -1.37)
- Co announced that reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2024 are expected to include acquired IPR&D and milestones expense of $82 million on a pre-tax basis, representing an unfavorable impact of $0.04 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.
- Co issues downside guidance for Q3 (Sep), sees EPS of $2.88-2.92, excluding non-recurring items, vs. $2.95 FactSet Consensus.
- Co issues downside guidance for FY24 (Dec), sees EPS of $10.67-10.87, excluding non-recurring items, vs. $10.88 FactSet Consensus.